ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results

Details

Language :

English

Database :

OpenAIRE

Journal :

Illidge, T, Horwitz, S M, O'Connor, O A, Pro, B, Iyer, S P, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T A, Menne, T, Belada, D, Illes, A, Tobinai, K, Tsukasaki, K, Yeh, S-P, Huettmann, A, Savage, K J, Yuen, S, Zinzani, P L, Miao, H, Bunn, V, Fenton, K, Fanale, M A, Puhlmann, M & Truemper, L 2021, ' ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results ', British Journal of Haematology, vol. 193, no. Suppl. 1, BSH2021-OR-039, pp. 38-40 . https://doi.org/10.1111/bjh.17490

Accession number :

edsair.od......3062..682443a44faba5e67b3d3b8470d359a8